TxCell: Lonza To Make CAR Tregs
Edison | Jun 12, 2018 07:48AM ET
Txcell (PA:TXCL) has announced that Lonza Group AG (SIX:LONN), the biopharmaceutical and cell manufacturing global specialist, will produce its CAR Tregs. TxCell uses a robust manufacturing design to give low inter-patient variability with potentially consistent therapeutic results. The time needed to transfer and validate the process in Lonza will push the IND filing to H119, formerly by Q418 but with security of supply. TxCell has drawn €5.4m of convertible loans ytd and is seeking longer-term funding or a partnering deal. The indicative valuation remains at €87.9m.
CAR Treg with multiple preclinical projects
TxCell aims to be the leading Treg company to treat immune disorders using chimeric antigen receptor (CAR) technology. In an ASCO discussion, Professor Carl June, MD, a pioneer of CAR-T therapy for cancer, noted that “Engineering T cells is a way to put the immune system on steroids and boost it to fight not just cancer but other chronic diseases…Companies are...investigating CAR T-cell therapy in organ transplantation to eliminate the need for lifelong immune-suppressants. The same principles that apply in the treatment of cancer apply to other diseases impacted by inflammation”. TxCell plans CAR Treg trials as a proof of concept in solid organ transplant.
To read the entire report Please click on the pdf File Below:
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.